A Chinese medicine composition for preventing and treating atherosclerosis and its application

Abstract

The present invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for preventing and treating atherosclerosis and its application, the traditional Chinese medicine composition is composed of artificial musk, ginseng total saponins, storax, salvia miltiorrhiza, atractylodes macrocephala, artificial bezoar, cinnamon bark, borneol, etc. The traditional Chinese medicine composition of the present invention has the effects of lowering blood lipid levels, improving oxidative stress, inhibiting inflammation, regulating intestinal flora disorder and reducing atherosclerotic plaques, and has a significant effect of improving atherosclerosis.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for preventing and treating atherosclerosis and its application. Background Art

[0002] Cardiovascular disease (CVD) is a disease with high mortality and disability rates worldwide. It is the number one killer of human health, with about 17.7 million people dying from cardiovascular disease each year. In China, atherosclerosis cardiovascular disease (ASCVD), represented by coronary heart disease and stroke, accounts for more than 40% of deaths from diseases among residents and is the leading cause of death among Chinese residents.

[0003] Atherosclerosis (AS) is the main pathological basis for the onset of cardiovascular diseases and the main cause of coronary heart disease. The pathological characteristics are inflammation, necrosis, fibrosis and calcification of the arterial intima, and plaque formation in specific parts of the arteries. The pathogenic factors of AS are relatively complex. It is currently believed that it is mainly related to vascular endothelial damage, inflammatory response, lipid metabolism disorders, and imbalance between autophagy and apoptosis. The conservative treatment drugs commonly used in modern medicine for the prevention and treatment of AS are mainly statins, which have achieved certain clinical efficacy, but the limitations of insufficient efficacy and drug side effects are gradually emerging.

[0004] Traditional Chinese medicine classifies coronary heart disease as "chest pain" and "heart pain". Zhang Zhongjing believed that "chest pain" is a type of disease with mixed deficiency and excess, and the overall pathogenesis is "weak yang and stringy yin". Traditional Chinese medicine compound has the characteristics of multi-component, multi-target and multi-pathway overall synergistic effect, showing unique advantages in the treatment of complex diseases such as cardiovascular diseases.

[0005] Musk Heart Pills and Musk Tongxin Dropping Pills are both commonly used Chinese patent medicines for the clinical treatment of coronary heart disease and angina pectoris in China. Musk Heart Pills and Musk Tongxin Dropping Pills are modern Chinese patent medicines developed on the basis of Suhexiang Pills in the famous Song Dynasty prescription book "Taiping Huimin Hejijufang". They have the effects of aromatic warming, invigorating qi and strengthening the heart, promoting blood circulation, removing blood stasis and relieving pain. They are mainly used for chest pain caused by qi stagnation and blood stasis or qi deficiency and blood stasis, with symptoms of precordial pain and immobility; angina pectoris caused by myocardial ischemia, myocardial infarction and the above symptoms. A large number of pharmacological and clinical studies have shown that Musk Heart Pills have the effects of increasing coronary flow, increasing cardiac output, resisting myocardial ischemia, promoting therapeutic angiogenesis, inhibiting the increase of serum TC and LDL-C concentrations, protecting the integrity of vascular endothelial cells and basement membranes, inhibiting vascular wall inflammation and intimal hyperplasia, improving myocardial metabolism, enhancing myocardial energy reserves, improving the body's ability to tolerate hypoxia, enhancing myocardial contractility, inhibiting platelet aggregation, and stabilizing myocardial cell membranes. Musk Tongxin Drops can protect endothelial function, dilate coronary arteries, reduce blood viscosity, and inhibit vascular inflammatory response.

[0006] Currently, the commonly used Western medicines for the treatment of atherosclerosis are severely limited in their application due to their contraindications or patients' inability to tolerate treatment. Musk Heart Pills and Musk Tongxin Drop Pills are effective in preventing and treating atherosclerosis, but they contain the traditional Chinese medicine Toad Venom, which is sweet and spicy, warm in nature, and toxic. While preventing and treating diseases, they may cause certain harm to the human body, limiting their dosage and duration of use.

[0007] In summary, the commonly used Western medicines and Chinese patent medicines for the prevention and treatment of atherosclerosis in modern medicine have limitations such as insufficient efficacy and side effects, which seriously restrict their widespread application. Summary of the invention

[0008] The purpose of the present invention is to solve the above technical problems and provide a new Chinese medicine composition for preventing and treating atherosclerosis. The new Chinese medicine composition obtained by removing toad venom from Shexiang Baoxin Pills and Shexiang Tongxin Dropping Pills has a significant anti-atherosclerotic effect, can reduce blood lipid levels, improve oxidative stress and inflammatory response, regulate intestinal flora disorders, and reduce ApoE - / - The atherosclerotic plaque formation in mice was reduced and the safety was higher.

[0009] The first aspect of the present invention provides a traditional Chinese medicine composition for preventing and treating atherosclerosis, which is composed of the following raw materials in parts by weight: 1-10 parts of artificial musk, 4-40 parts of ginsenosides, 1-10 parts of storax, 2-20 parts of atractylodes, 4-40 parts of salvia miltiorrhiza, 7-70 parts of cinnamon, 6-60 parts of artificial bezoar, and 10-80 parts of borneol.

[0010] Furthermore, the Chinese medicine composition for preventing and treating atherosclerosis is composed of the following raw materials in parts by weight: 1-5 parts of artificial musk, 4-8 parts of ginsenosides, 1-2 parts of storax, 2-5 parts of atractylodes, 4-6 parts of salvia miltiorrhiza, 7-15 parts of cinnamon, 6-7 parts of artificial bezoar, and 10-25 parts of borneol.

[0011] Furthermore, the Chinese medicine composition for preventing and treating atherosclerosis is composed of the following raw materials in parts by weight: 1 part of artificial musk, 8 parts of ginsenosides, 2 parts of storax, 5 parts of atractylodes, 4 parts of salvia miltiorrhiza, 15 parts of cinnamon, 7 parts of artificial bezoar, and 25 parts of borneol.

[0012] The second aspect of the present invention provides a pharmaceutical preparation having the above-mentioned Chinese medicine composition for preventing and treating atherosclerosis as an active ingredient, wherein the pharmaceutical preparation is prepared into a commonly used dosage form in pharmacy by conventional preparation methods in the art.

[0013] Furthermore, the pharmaceutical preparation may be in a unit dosage form, such as a decoction, a capsule (including a sustained-release or delayed-release form), a tablet, a pill or a granule, preferably a pill or a capsule for oral administration.

[0014] Furthermore, the pharmaceutical preparation also includes pharmaceutically acceptable excipients. Among them, "pharmaceutically acceptable excipients" are well known to those skilled in the art, including pharmaceutically acceptable carriers, excipients, diluents, etc., which are compatible with the active ingredients. The specific preparation ratio depends on the ingredients of each excipient.

[0015] Furthermore, the pharmaceutical preparation can be prepared by the following method: (A) weighing the various medicinal components, mixing them, and obtaining a mixture; (B) adding a pharmaceutically acceptable carrier or excipient to the mixture and preparing the mixture by a conventional preparation method in the art.

[0016] The third aspect of the present invention provides a use of the above-mentioned traditional Chinese medicine composition in the preparation of a drug for preventing and treating atherosclerosis.

[0017] Furthermore, the atherosclerosis includes one or more of atherosclerosis caused by various factors such as hyperlipidemia, obesity, hyperglycemia, and heredity.

[0018] Furthermore, the Chinese medicine composition reduces the formation of atherosclerotic plaques induced by hyperlipidemia.

[0019] Furthermore, the Chinese medicine composition reduces blood lipid levels, improves oxidative stress, improves inflammatory response, and regulates intestinal flora disorders.

[0020] Musk in the formula is used to warm the yang, activate blood circulation and dissipate blood stasis, while ginseng is used to strengthen the body and replenish qi, promote the production of body fluid and nourish blood as the main medicine; storax is used to dispel filth and clear the orifices, white atractylodes is used to strengthen the spleen and replenish qi, eliminate dampness and promote diuresis, and salvia is used to activate blood circulation and dissipate blood stasis, promote menstruation and relieve pain as the assistant medicine; bezoar is used to open the orifices and wake up the mind, eliminate phlegm and detoxify, cinnamon is used to warm the middle and dissipate cold, regulate qi and relieve pain as the adjuvant medicine; borneol is used to open the orifices and wake up the mind as the guiding medicine. The whole formula uses both cold and warm, promotes and replenishes qi, and strengthens the heart, which together play the effects of nourishing qi and yin, activating blood circulation and eliminating phlegm, activating blood circulation and removing blood stasis, and clearing away heat and detoxifying.

[0021] The present invention first discovered the therapeutic effect of the recombined Chinese medicine composition of the present invention on the formation of atherosclerotic plaques. - / - ) mice for 12 weeks to create an atherosclerosis model, and the mice were given oral administration of a low-dose Chinese medicine composition (28 mg / kg / day for 12 weeks) and a high-dose Chinese medicine composition (112 mg / kg / day for 12 weeks). The results suggest that the Chinese medicine composition of the present invention significantly alleviates HFD-induced ApoE - / - The accumulation of atherosclerotic plaques in the aortic arch, aortic intima and aortic valve of mice increased (Example 10). At the same time, the present invention detected the blood lipid levels of each group of mice, and the results showed that the Chinese medicine composition of the present invention can significantly reduce the ApoE induced by HFD. - / - The Chinese medicine composition of the present invention effectively inhibits HFD-induced ApoE - / - The serum oxidative stress level of mice increased (Example 11). The Chinese medicine composition of the present invention significantly inhibited the HFD-induced ApoE - / - The serum inflammation level of mice increased (Example 12). The Chinese medicine composition of the present invention significantly regulates HFD-induced ApoE - / - Mouse intestinal flora disorder (Example 13). The Chinese medicine composition of the present invention can inhibit the formation of foam cells in mouse RAW264.7 cells induced by oxidized low-density lipoprotein (OxLDL 60 μg / ml), and reduce the total cholesterol and cholesterol lactone levels in mouse RAW264.7 cells (Example 14).

[0022] The present invention has the advantages that:

[0023] The Chinese medicine composition of the present invention has the effects of lowering blood lipid levels, improving oxidative stress, inhibiting inflammation, regulating intestinal flora disorders and reducing atherosclerotic plaques, and has a significant effect on improving atherosclerosis, has the potential advantages of good efficacy, greater safety, and suitability for long-term use, as well as higher clinical application value; the present invention reduces the toxicity of the Chinese medicine compound on the basis of effectively preventing and treating atherosclerosis by removing toad venom and re-formulating the formula, and is safer and more advantageous for wide clinical application. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1The Chinese medicine composition of the present invention is effective in treating HFD-induced ApoE - / - Diagram of the effects of increased atherosclerotic plaque accumulation in mice.

[0025] Figure 2 The Chinese medicine composition of the present invention is effective in treating HFD-induced ApoE - / - Effect diagram of changes in blood lipid levels in mice.

[0026] Figure 3 The Chinese medicine composition of the present invention is effective in treating HFD-induced ApoE - / - Effect diagram of altered oxidative stress levels in mice.

[0027] Figure 4 The Chinese medicine composition of the present invention is effective in treating HFD-induced ApoE - / - Effect diagram of changes in inflammatory levels in mice. Note: Compared with the normal group, *p<0.05, **P<0.01, ***P<0.001; compared with the model group, #P<0.05, ##P<0.01, ###P<0.001.

[0028] Figure 5 The Chinese medicine composition of the present invention is effective for HFD-induced ApoE - / - Effect diagram of intestinal microbial diversity in mice. Note: Compared with the normal group, *p<0.05, **P<0.01, ***P<0.001; compared with the model group, #P<0.05, ##P<0.01, ###P<0.001.

[0029] Figure 6 The present invention Chinese medicine composition inhibits the formation of foam cells by mouse RAW264.7 cells induced by oxidized low-density lipoprotein (OxLDL 60 μg / ml) and the present invention Chinese medicine composition affects the total cholesterol and cholesterol lactone in mouse RAW264.7 cells induced by oxidized low-density lipoprotein (OxLDL 60 μg / ml). DETAILED DESCRIPTION

[0030] The specific implementation methods provided by the present invention are described in detail below in conjunction with examples.

[0031] Embodiment 1: Chinese medicine composition of the present invention

[0032] The invention is composed of the following raw materials in parts by weight: 1 part of artificial musk, 8 parts of ginsenosides, 2 parts of storax, 5 parts of atractylodes macrocephala, 4 parts of salvia miltiorrhiza, 15 parts of cinnamon bark, 7 parts of artificial bezoar and 25 parts of borneol.

[0033] Embodiment 2: Chinese medicine composition of the present invention

[0034] The invention is composed of the following raw materials in parts by weight: 2 parts of artificial musk, 4 parts of ginsenosides, 1 part of storax, 2 parts of atractylodes macrocephala, 6 parts of salvia miltiorrhiza, 7 parts of cinnamon bark, 6 parts of artificial bezoar and 10 parts of borneol.

[0035] Embodiment 3: Chinese medicine composition of the present invention

[0036] The invention is composed of the following raw materials in parts by weight: 5 parts of artificial musk, 16 parts of ginsenosides, 5 parts of storax, 8 parts of atractylodes macrocephala, 20 parts of salvia miltiorrhiza, 30 parts of cinnamon bark, 20 parts of artificial bezoar and 40 parts of borneol.

[0037] Embodiment 4: Chinese medicine composition of the present invention

[0038] The invention is composed of the following raw materials in parts by weight: 8 parts of artificial musk, 30 parts of ginsenosides, 8 parts of storax, 14 parts of atractylodes macrocephala, 30 parts of salvia miltiorrhiza, 50 parts of cinnamon bark, 40 parts of artificial bezoar and 60 parts of borneol.

[0039] Embodiment 5: Chinese medicine composition of the present invention

[0040] The invention is composed of the following raw materials in parts by weight: 10 parts of artificial musk, 40 parts of ginsenosides, 10 parts of storax, 20 parts of atractylodes macrocephala, 40 parts of salvia miltiorrhiza, 70 parts of cinnamon bark, 60 parts of artificial bezoar and 80 parts of borneol.

[0041] Example 6: Preparation of decoction

[0042] The conventional preparation method of Chinese herbal decoction is adopted, that is, the Chinese herbal composition described in any one of Examples 1-5 is weighed, and water is added to boil it into a decoction.

[0043] Example 7: Preparation of tablets / capsules

[0044] Weigh the Chinese medicine composition described in any one of Examples 1-5, grind it into powder, decoct it, and concentrate it under reduced pressure to obtain an extract. Dry and crush the extract into granules, add pharmaceutical excipients, and press it into tablets or fill it into capsules.

[0045] Example 8: Preparation of granules

[0046] Weigh the Chinese medicine composition described in any one of Examples 1-5, grind it into powder, decoct it, and concentrate it under reduced pressure to obtain an extract, which is then dried and crushed to prepare granules.

[0047] Example 9: Preparation of pills

[0048] Weigh the Chinese medicine composition described in any one of Examples 1-5, grind it into powder, decoct it, take the supernatant, and concentrate it into a thick extract; add appropriate pharmaceutical excipients (such as sugar, honey, benzopropionic acid or ethylparaben) to make pills.

[0049] Example 10: Effect of the Chinese medicine composition of the present invention on HFD-induced ApoE - / -Effects of increased atherosclerotic plaque accumulation in mice

[0050] ApoE in male C57BL / 6 background - / - Mice were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. and raised in the Animal Experiment Center of the Naval Medical University. Mice were raised in an animal room with a constant temperature and 12-12h day and night rhythm using standard rodent food and water. The animals spent at least one week to adapt to the environment before the start of the experiment. All protocols involving animal use were approved by the Ethics Committee of the Naval Medical University. The Toad Venom-Deficient Musk Heart Pills used in the experiment were prepared in a formulation that can be dissolved in 0.5% CMC-Na. 8-week-old male ApoE - / - The mice were randomly divided into 4 groups: normal feeding group, high-fat feeding group, high-fat feeding + low concentration of the Chinese medicine composition of the present invention, and high-fat feeding + high concentration of the Chinese medicine composition of the present invention, with 10 mice in each group. The normal diet contained 10 kcal% fat and no cholesterol, and the high-fat diet contained 40 kcal% fat and 1.25 kcal% cholesterol; the Chinese medicine composition of the present invention was administered by gavage (low dose 28 mg / kg / d for 12 weeks and high dose 112 mg / kg / d for 12 weeks). The results showed that the Chinese medicine composition of the present invention significantly alleviated HFD-induced ApoE - / - Increased accumulation of atherosclerotic plaques in the aortic arch of mice ( Figure 1 A). The results of Oil Red O staining indicate that the Chinese medicine composition of the present invention significantly alleviates HFD-induced ApoE - / - Mouse aortic intima ( Figure 1 BC) and aortic valve ( Figure 1 DE) atherosclerotic plaque accumulation increased. At the same time, the present invention detected the blood lipid levels of each group of mice, and the results showed that the Chinese medicine composition of the present invention can affect the changes in blood lipids of mice, such as increased total cholesterol (TC), increased triglycerides (TG), increased low-density lipoprotein (LDL), and decreased high-density lipoprotein (HDL). The above results indicate that the Chinese medicine composition of the present invention has a therapeutic effect on the formation of atherosclerotic plaques, and this effect is partially achieved by regulating blood lipids.

[0051] in, Figure 1 A represents the effect of the Chinese medicine composition of the present invention on the alleviation of HFD-induced ApoE under light microscopy. - / - Atherosclerotic plaque formation in the aortic arch of mice; Figure 1 B represents the whole aorta specimen stained with Oil Red O, showing that the Chinese medicine composition of the present invention alleviates the formation of atherosclerotic plaques in the aorta intima of ApoE- / - mice induced by HFD; Figure 1 C stands for Figure 1 Statistical graph of relative plaque area of ​​each group in B; Figure 1 D represents the aorta root specimen stained with HE, showing that the Chinese medicine composition of the present invention alleviates HFD-induced ApoE- / - Atherosclerotic plaque formation in mouse aortic valves; Figure 1 E represents the statistics of aortic root plaque area. The above results show that the Chinese medicine composition of the present invention alleviates ApoE induced by high-fat feeding. - / - Increased accumulation of atherosclerotic plaques in the aorta of mice.

[0052] in, Figure 2 The results show that the Chinese medicine composition of the present invention has an effect on HFD-induced ApoE - / - Effects of blood lipids on mice; Figure 2 A represents that the Chinese medicine composition of the present invention significantly reduces HFD-induced ApoE - / - The serum TC level of mice increased; Figure 2 B represents that the Chinese medicine composition of the present invention significantly reduces HFD-induced ApoE - / - The serum TG content of mice increased; Figure 2 C represents that the Chinese medicine composition of the present invention reduces HFD-induced ApoE - / - The serum LDL level of mice increased; Figure 2 D represents that the Chinese medicine composition of the present invention increases the HFD-induced ApoE - / - The serum HDL level of mice was decreased.

[0053] Example 11: Effect of the Chinese medicine composition of the present invention on HFD-induced ApoE - / - Effects of elevated serum oxidative stress levels in mice

[0054] The levels of serum oxidative stress markers, such as superoxide dismutase (SOD), reduced glutathione (GSH), and malondialdehyde (MDA), in each group of mice were detected. The results showed that the Chinese medicine composition of the present invention can improve the serum oxidative stress level of mice, thereby achieving the effect of treating atherosclerosis.

[0055] in, Figure 3 The results show that the Chinese medicine composition of the present invention has an effect on HFD-induced ApoE - / - Figure 1. Effects of oxidative stress status on mice; Figure 3 A indicates that the Chinese medicine composition of the present invention significantly increases HFD-induced ApoE - / - The serum SOD level of mice was reduced; Figure 3 B indicates that the Chinese medicine composition of the present invention significantly increases HFD-induced ApoE - / - The serum GSH content of mice was reduced; Figure 3 C represents that the Chinese medicine composition of the present invention reduces HFD-induced ApoE - / - The serum MDA content of mice was increased.

[0056] Example 12: Effect of the Chinese medicine composition of the present invention on HFD-induced ApoE - / -Effects of elevated serum inflammatory factor levels in mice

[0057] The serum levels of interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) in each group of mice were detected. The results showed that the Chinese medicine composition of the present invention can improve HFD-induced ApoE - / - Serum inflammatory factor levels in mice.

[0058] in, Figure 4 The results show that the Chinese medicine composition of the present invention has an effect on HFD-induced ApoE - / - Effect diagram of serum inflammatory factor levels in mice; Figure 4 A represents that the Chinese medicine composition of the present invention significantly reduces HFD-induced ApoE - / - The serum IL-1β level of mice increased; Figure 4 B represents that the Chinese medicine composition of the present invention significantly reduces HFD-induced ApoE - / - The serum IL-6 level of mice was elevated. Figure 4 C represents that the Chinese medicine composition of the present invention significantly reduces HFD-induced ApoE - / - The serum TNF-α level of mice was elevated.

[0059] Example 13: Effect of the Chinese medicine composition of the present invention on HFD-induced ApoE - / - Effects of regulating intestinal flora disturbance in mice

[0060] The intestinal microbial diversity of each group of mice was detected, and the results showed that the Chinese medicine composition of the present invention can significantly increase HFD-induced ApoE - / - Reduced intestinal microbiota richness in mice regulates HFD-induced ApoE - / - The structure and composition of the intestinal flora of mice are disordered at the phylum and genus classification levels.

[0061] in, Figure 5 The Chinese medicine composition of the present invention has an effect on HFD-induced ApoE - / - Effect diagram of microbial diversity in the mouse gut microbiota; Figure 5 A indicates that the Chinese medicine composition of the present invention significantly increases HFD-induced ApoE - / - The richness of the intestinal flora of mice was reduced; Figure 5 B represents that the Chinese medicine composition of the present invention significantly regulates HFD-induced ApoE - / - The structure and composition of the mouse intestinal flora; Figure 5 C represents that the Chinese medicine composition of the present invention significantly regulates the structural composition and differential bacterial phyla of the intestinal flora of ApoE- / - mice induced by HFD; Figure 5 D indicates that the Chinese medicine composition of the present invention significantly regulates HFD-induced ApoE - / -The structural composition and differential genera of the mouse intestinal flora in terms of genus classification.

[0062] Example 14: Effects of the Chinese herbal composition of the present invention on foam cell formation and intracellular cholesterol (TC) and cholesterol lactone (CE) of RAW264.7 cells induced by OxLDL

[0063] In vitro, 60 μg / ml OxLDL was used to induce RAW264.7 cells (Shanghai Chinese Academy of Sciences Cell Bank) to form a foam cell model. After low-dose and high-dose treatments with the Chinese medicine composition of the present invention, the drug was observed to inhibit the formation of foam cells in RAW264.7 cells. The specific method is as follows: 5*10 5 / ml RAW264.7 cells were cultured with DMEM culture medium at 37℃. After 24 hours, the culture medium was renewed and divided into four groups: normal group (DMEM), model group (DMEM+60μg / ml OxLDL), low-dose administration group (DMEM+60μg / ml OxLDL+25μg / ml drug extract) and high-dose administration group (DMEM+60μg / ml OxLDL+100μg / ml drug extract). After each group was cultured with the corresponding new culture medium for 24 hours, the formation of foam cells was observed by oil red staining ( Figure 6 A), Cell cholesterol detection kit (Beijing Pulilai Gene Technology Co., Ltd., E1015) was used to detect the total cholesterol level in cells ( Figure 6 B), free cholesterol detection kit (Beijing Pulilai Gene Technology Co., Ltd., E1016) was used to detect the level of intracellular free cholesterol ( Figure 6 B), the result was divided by the corresponding total protein concentration for accuracy, each index was measured 3 times, and the average value and error value were calculated. The results showed that the Chinese medicine composition of the present invention can inhibit the formation of foam cells by OxLDL-induced RAW264.7 cells, and reduce the levels of total cholesterol and cholesterol lactone in RAW264.7 cells induced by OxLDL.

[0064] in, Figure 6 A represents pictures of different groups of RAW264.7 cells after oil red staining under a 10x40 inverted microscope. The results show that foam cells are obviously formed in the model group (Model), and the oil red staining is deep. Different concentrations of the Chinese medicine composition of the present invention can inhibit the formation of foam cells in mouse RAW264.7 cells induced by OxLDL and reduce the staining of RAW264.7 cells by oil red.

[0065] in, Figure 6 B represents the levels of cholesterol and cholesterol lactone in RAW264.7 cells in different groups. The results show that the Chinese medicine composition of the present invention can reduce the increase of TC and CE in RAW264.7 cells induced by OxLDL.

[0066] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. A Chinese medicine composition for preventing and treating atherosclerosis, characterized in that: The invention is composed of the following raw materials in parts by weight: 1-10 parts of artificial musk, 4-40 parts of ginsenosides, 1-10 parts of storax, 2-20 parts of atractylodes macrocephala, 4-40 parts of salvia miltiorrhiza, 7-70 parts of cinnamon bark, 6-60 parts of artificial bezoar and 10-80 parts of borneol.

2. The Chinese medicine composition for preventing and treating atherosclerosis according to claim 1, characterized in that: The invention is composed of the following raw materials in parts by weight: 1-5 parts of artificial musk, 4-8 parts of ginsenosides, 1-2 parts of storax, 2-5 parts of atractylodes macrocephala, 4-6 parts of salvia miltiorrhiza, 7-15 parts of cinnamon bark, 6-7 parts of artificial bezoar and 10-25 parts of borneol.

3. The Chinese medicine composition for preventing and treating atherosclerosis according to claim 1, characterized in that: The invention is composed of the following raw materials in parts by weight: 1 part of artificial musk, 8 parts of ginsenosides, 2 parts of storax, 5 parts of atractylodes macrocephala, 4 parts of salvia miltiorrhiza, 15 parts of cinnamon bark, 7 parts of artificial bezoar and 25 parts of borneol.

4. A pharmaceutical preparation comprising the Chinese medicine composition for preventing and treating atherosclerosis as claimed in any one of claims 1 to 3 as an active ingredient, characterized in that: The pharmaceutical preparation is prepared into a common dosage form in pharmacy by conventional preparation methods in the art.

5. The pharmaceutical preparation according to claim 4, characterized in that The pharmaceutical preparation is a decoction, capsule, tablet, pill or granule.

6. The pharmaceutical preparation according to claim 5, characterized in that The pharmaceutical preparation also includes pharmaceutically acceptable excipients.

7. Use of the Chinese medicine composition according to any one of claims 1 to 3 in the preparation of a drug for preventing and treating atherosclerosis.

8. The use according to claim 7, characterized in that: The atherosclerosis is caused by one or more than two of the following factors: hyperlipidemia, obesity, hyperglycemia, and genetics.

9. The use according to claim 7, characterized in that: The traditional Chinese medicine composition reduces the formation of atherosclerotic plaques induced by hyperlipidemia.

10. The use according to claim 7, characterized in that: The Chinese medicine composition reduces blood lipid levels, improves oxidative stress, improves inflammatory response, and regulates intestinal flora disorders.

Images